August 5, 2021
UC San Diego researchers report that solid organ transplant recipients who were vaccinated experienced an almost 80 percent reduction in the incidence of symptomatic COVID-19 compared to unvaccinated counterparts during the same time.
March 18, 2015
Researchers at the San Diego Supercomputer Center (SDSC) and the Moores Cancer Center at the University of California, San Diego, have described for the first time the molecular mechanism of cancer development caused by well-known “resistance” mutations in the gene called epidermal growth factor receptor (EGFR).
August 13, 2014
Our immune system copes with a multitude of threats using a mix-and-match system to create millions of different antibodies.
November 3, 2022
This season there are three prevalent respiratory viruses to be aware of—influenza, SARS-CoV-2 and respiratory syncytial virus (RSV), all of which are transmitted via aerosols.
January 16, 2024
A vaccine for Staphylococcus aureus, one of the most common bacterial infections, would be a game changer for public health. No vaccine candidates have succeeded in clinical trials, but nobody knows why. Researchers at UC San Diego may have figured it out.
March 9, 2018
…a standard of care drug with a novel monoclonal antibody that target B-cell malignancies, which include leukemias and lymphomas.
August 24, 2017
The Independent Citizens Oversight Committee of the California Institute for Regenerative Medicine (CIRM) today unanimously approved an $18.29 million grant to University of California San Diego School of Medicine researchers to fund a phase Ib/IIa clinical trial of a novel combination drug therapy for B-cell cancers.
November 18, 2021
…fighting chance, having the antibodies to fight off everything if they were exposed to it. And I’m just grateful that I have access to that because other countries don’t have the same opportunities we have.” After a whirlwind year, Faniel and her partner welcomed a healthy baby boy to the…
June 1, 2018
…have found that treatment with cirmtuzumab, an experimental monoclonal antibody-based drug, measurably inhibited the “stemness” of chronic lymphocytic leukemia cancer (CLL) cells — their ability to self-renew and resist terminal differentiation and senescence.
December 13, 2013
Researcher Thomas J. Kipps, MD, PhD, professor of medicine and deputy director of research operations at UC San Diego Moores Cancer Center, is principal investigator for one of six “Disease Team” awards approved December 12 by the governing board of the California Institute for Regenerative Medicine (CIRM).
